H epatitis B virus (HBV) infection remains a
world-wide public health challenge with an estimated 2 billion people infected and over 1 million deaths annually attributed to fulminant hepatitis B, cirrhosis, and hepatocellular carcinoma (HCC).
(1) Liver disease associated with chronic hepatitis B (CHB) is induced by inflammatory processes initiated when the host immune response attempts to Abbreviations: AAs, arachidonic acids; AIC, Akaike information criterion; ALD, alcoholic liver disease; ALT, alanine aminotransferase; BMI, body mass index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; CI, confidence interval; CT, threshold cycle; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HGDP, Human Genome Diversity Project; LD, linkage disequilibrium; MAF, minor allele frequency; MBOAT7, membrane-bound Oacyltransferase domain-containing 7; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; PNPLA3, patatin-like phospholipase domaincontaining protein 3; SMAD4, small mothers of decapentaplegic 4; SNP, single-nucleotide polymorphism; T2DM, type 2 diabetes mellitus; TGF, transforming growth factor; TM6SF2, transmembrane 6 superfamily member 2; UTR, untranslated region.
eliminate the virus, and its persistence and severity plays a pivotal role in disease progression and the development of complications. In addition, a complex interplay between host genetics, immune response, and viral factors modulates the final outcome of infection. (2) Recently, several reports have consistently demonstrated that single-nucleotide polymorphisms (SNPs; rs641738) near the membrane bound OAcyltransferase domain-containing 7 gene (MBOAT7) impact inflammation and fibrosis in patients with alcoholic cirrhosis, (3) nonalcoholic fatty liver disease (NAFLD), (4, 5) and chronic hepatitis C (CHC), (6) but no data are yet available for CHB. MBOAT7 (Lysophospholipid acyltransferase) belongs to the remodeling pathway of phosphoinositides (Land's cycle) that attaches arachidonic acids (AAs) to lysophosphatidylinositol (7) to reduce free AA levels. AA also induces apoptosis, (8) a potent trigger for liver inflammation and fibrosis, (9) and amplifies the inflammatory response in macrophages and other immune cells. (10) The rs641738 (T) allele that is associated with an increased risk of hepatic inflammation is coupled to decreased hepatic MBOAT7 mRNA and protein expression, as well as reduced arachidonoyl-phosphatidylinositol/ total phosphatidylinositol ratios, indicating attenuated enzymatic activity. (4) (5) (6) Furthermore, we have shown strong MBOAT7 expression in virtually all common immune cell subsets that infiltrate the liver during viral hepatitis. (6) These data suggest a potential role for MBOAT7 activity in modulating inflammation independent of the etiology of liver disease.
In this study, we explored the role of MBOAT7 rs641738 in the liver damage phenotype (inflammation and fibrosis) of a large multiethnic cohort of 1,101 treatment-na€ ıve patients with CHB. We subsequently undertook functional analysis of the rs641738 polymorphism.
Patients and Methods

PATIENT COHORT
We enrolled a cohort of 1,101 consecutive treatment-na€ ıve CHB patients examined by percutaneous liver biopsy (598 
PRIMARY OUTCOME AND POWER ANALYSIS
The primary outcome was liver damage (inflammation and fibrosis). A power analysis was performed using the G*power program (11) based on Cohen's method. (12) The sample size had >80% power to detect a significant association (a < 0.05) with an effect size index of 0.1 (corresponding to a weak gene effect) for the primary association with liver damage.
CLINICAL AND LABORATORY ASSESSMENT
The following data were collected at time of liver biopsy: sex, age, ethnicity, recruitment center, alcohol intake (g/day), body mass index (BMI), HBV-DNA level, hepatitis B e antigen (HBeAg) status, and routine laboratory tests within 6 months from time of liver biopsy. BMI was calculated as weight divided by the square of the height (kg/m 2 ). Positive alcohol intake was defined in the presence of reported regular consumption of any amount of alcohol 1 unit/day during the last 1 year, as reported. (13) HBV phenotype designation was based on published definitions (14) (15) (16) using a single ALT and HBV-DNA value at time of biopsy, as follows: (1) immune tolerant: HBeAg positive, normal serum ALT levels, and HBV-DNA levels 10 5 IU/mL; (2) immune active: a) HBeAg positive, elevated ALT levels, and HBV-DNA levels 10 5 IU/mL and (b) HBeAg negative, elevated ALT levels, and HBV-DNA levels 10 4 IU/mL; (3) the inactive carrier: HBeAg negative, normal serum ALT levels, and HBV DNA (10 4 IU/ mL); and (4) indeterminate: subjects who did not fit into one of these categories.
GENOTYPING
Genotyping for MBOAT7 rs641738, PNPLA3 rs738409, and TM6SF2 rs58542926 was undertaken by the TaqMan SNP genotyping allelic discrimination method (Applied Biosystems, Foster City, CA). Some rs738409 and rs58542926 genotyping was extracted from our previous report. (17) All genotyping was blinded to clinical variables.
LIVER HISTOPATHOLOGY
Scoring of liver biopsies was performed by a single expert pathologist in each center unaware of patient status and genotype according to METAVIR. (18) All biopsies had a minimum of 11 portal tracts, and inadequate biopsies were excluded. This information was provided in publications using this cohort. (19, 20) Fibrosis was staged from F0 (no fibrosis) to F4 (cirrhosis). Hepatic inflammation (A) was graded as A0 (absent), A1 (mild), A2 (moderate), or A3 (severe). Steatosis was quantified as follows: grade 0: absent or <5% of hepatocytes involved; grade 1: 5%-33%; grade 2: 34%-66%; and grade 3: >66% of hepatocytes affected. Interobserver agreement between pathologists was studied and was good (j 5 77.5) for METAVIR staging using j statistics. 
POPULATION GENETIC ANALYSIS
The global distribution of the MBOAT7 rs641738 allele among 53 populations was derived from the Human Genome Diversity Project (HGDP) browser (http://hgdp.uchicago.edu/). (22) Functional annotation of rs641738 was using HaploRegv4 default settings. (23) HaploReg intersects SNPs with functional regions identified by the ENCODE project.
GENE EXPRESSION ANALYSIS
To determine the functional consequences of MBOAT7 rs641738 in CHB, we examined expression according to rs641738 genotype in a well-characterized cohort of patients (n 5 42). Subjects were chosen based solely on fulfilling the inclusion and exclusion criteria of the study and having stored liver tissue available for analysis. RNA was extracted using the RNeasy kit (Qiagen, Germany), according to the manufacturer's instructions. RNA quality and concentration was assessed using the Agilent 2100 Bioanalyser (Agilent, Waldbronn, Germany). Complementary DNA was prepared using qscript (Quanta Biosciences, Gaithersburg, MD) in a Mastercycler gradient 5331 (Eppendorf AG, Hamburg, Germany). Gene expression for MBOAT7 was measured by qPCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the house keeping gene. Expression was measured using threshold cycle (CT) values, normalized to that of GAPDH (DCT5 CT [GAPDH] -CT [target]) and then expressed as 2
DCT . All amplifications were done in duplicate.
STATISTICAL ANALYSIS
Statistical analyses were performed using the statistical software package, SPSS for Windows (version 21; SPSS, Inc., Chicago, IL). Results are expressed as mean 6 SD, median and range, or number (percentage) of patients. The Student t test or no-parametric (i.e., WilcoxonMann-Whitney U test or Kruskal-Wallis) tests were used to compare quantitative data, as appropriate. v 2 and Fisher's exact tests were used for comparison of frequency data and to evaluate the relationships between groups. The Cochran-Armitage test was used for trend analysis. All tests were two-tailed, and P values <0.05 were considered significant. Genetic analyses were performed assuming an additive model of inheritance; that is, the genotype is coded with 0, 1, or 2 corresponding to the number of minor alleles carried by each individual. In a further analysis, rs641738 was coded in a dominant model for the minor allele (T) because our previous data demonstrated that this model best fitted the data and was the most appropriate because it had the lowest Akaike information criterion (AIC) value. (6) Multiple logistic regression models were fitted to binary traits; inflammation was dichotomized as absent/ mild (METAVIR score A0-A1) or moderate/severe (METAVIR score A2-A3) and fibrosis as absent/mild (METAVIR score F0-F1) or significant (METAVIR score F2-F4). In secondary analysis, steatosis was dichotomized as absent/mild (S0-S1) or moderate/ severe (S2-S3). The odds ratio (OR) estimates the relative change in the rate of the outcome (e.g., significant fibrosis) per unit increase in the explanatory variable. Apart from MBOAT7 rs641738, multivariate logistic regression analysis incorporated biologically relevant covariates associated with the risk of liver disease progression (age, sex, BMI, presence of type 2 diabetes mellitus [T2DM], recruiting center, viral load, ALT, ethnicity, HBeAg status, and PNPLA3 rs738409 and TM6SF2 rs58542926 genotype). HBV-DNA levels were log-transformed before entry into the model. Results are expressed as ORs and 95% confidence interval (CI). The association between the MBOAT7 rs641738 variant and histological features (severity of inflammation, fibrosis, and steatosis) was also tested by multivariate ordinal regression models with the same variables listed above as covariates. Multiple imputation for alcohol intake missing values was performed as recommended (24, 25) and undertaken by us recently. (20) Results
MBOAT7 rs641738 MINOR ALLELE FREQUENCY IN THE HBV COHORT
The clinical, anthropometric, and biochemical characteristics of the patients are presented in Supporting  Table S1 . The minor allele (T) frequency (MAF) was 0.44 in whites and 0.24 in Chinese (Fig. 1) ; these frequencies are similar to those observed in healthy white and Chinese populations from the 1000 Genomes Project.
(26) The genotype distributions were in HardyWeinberg equilibrium in both ethnic groups (all P > 0.05; Supporting Table S2 ). In white subjects, there was no difference in rs641738 allele frequency distribution according to patient country of origin (P 5 0.4 for trend by the Cochran-Armitage test). To examine for the detailed global allelic frequency distributions of MBOAT7 rs641738, we queried the HGDP browser (22) to compare allele frequencies in 53 world populations. Intriguingly, rs641738 showed wide differences in derived allele frequency (T allele), with the highest in Europe and South Asia, followed by North and Southern Africa and lowest in East Asia (Fig. 1) .
ASSOCIATION BETWEEN MBOAT7 rs641738 AND VIRAL, CLINICAL AND METABOLIC CHARACTERISTICS
Data according to rs641738 genotype in the whole population is shown in Supporting Table S3 . Apart from the fact that ALT levels were higher in subjects carrying the (T) allele (P 5 0.03), no other differences in clinical, anthropometric, alcohol intake, or viral indices were found according to rs641738 genotype. When the analysis was stratified by ethnic groups, no differences in any characteristics were found according to rs641738 genotype (Supporting Table S4 ).
MBOAT7 rs641738 INCREASES HEPATIC INFLAMMATION SEVERITY
In multiple logistic regression analysis adopting an additive model for genetic analysis adjusted for covariates, including age, sex, BMI, T2DM, recruitment center, PNPLA3 and TM6SF2 genotypes, viral load, ALT, ethnicity, and HBeAg status, carriage of each copy of the (T) allele was associated with advanced inflammation (A2-A3; OR 5 1.44; 95% CI, 1.07-1.96; P 5 0.001). When the analysis was stratified by ethnic group, the association remained significant only in whites (OR 5 1.24; 95% CI, 1.02-2.04; P 5 0.03).
The estimated OR in Chinese was directionally consistent (OR 5 1.16), but not significant (P 5 0.1; Table  1 ). For further confirmation, in multivariate ordinal regression analysis adjusting for the same variables, rs641738 was again associated with severity of inflammation (P 5 0.002; Fig. 2) . Genetic analyses were undertaken using an additive model for PNPLA3 and MBOAT7 and a dominant model for TM6SF2 (because of only a few homozygotes for the 167K mutant allele).
MBOAT7 rs641738 INCREASES HEPATIC FIBROSIS SEVERITY
Next, we tested the association of rs641738 with fibrosis stage. As for inflammation, in multiple logistic regression analysis adjusted for the covariates listed above, each copy of the (T) allele conferred an increased risk of significant fibrosis (F2-F4; OR 5 1.32; 95% CI, 1.20-1.93; P 5 0.01). When the analysis was stratified by ethnic group, the association was significant in whites (OR 5 1.19; 95% CI, 1.07-2.13; P 5 0.05) and directionally consistent in Chinese (OR 5 1.09; Table 2 ). In multivariate ordinal regression analysis adjusting for the same variables, rs641738 remained associated with the severity of fibrosis (P 5 0.02; Fig. 2) .
Importantly, rs641738 did not associate with alcohol intake (Supporting Tables S3 and S4 ). The association with inflammation and fibrosis remained virtually the same after additional adjustment for alcohol intake or even after multiple imputation for alcohol intake missing values. For the latter, the OR for inflammation was 1.45 (95% CI, 1.05-1.94; P 5 0.001) and for fibrosis 1.30 (95% CI, 1.17-1.91; P 5 0.01).
MBOAT7 rs641738 AND INFLAMMATION AND FIBROSIS IN OTHER GENETIC MODELS OF INHERITANCE
We analyzed the association of rs641738 with severity of liver damage assuming a dominant model for the minor allele (T), because we have previously shown that this best fitted the data and had the lowest AIC value. (6) In this analysis, the (T) allele was estimated to have an even greater risk for severe inflammation and fibrosis compared with homozygotes for the (C) allele (Supporting Fig. S1 ).
ROLE OF PNPLA3 AND TM6SF2 GENOTYPE ON INFLAMMATION AND FIBROSIS
Because PNPLA3 rs738409 and TM6SF2 rs58542926 have been associated with the risk of alcoholic cirrhosis (3) and with liver damage across other liver diseases, (17, 27, 28) we evaluated whether they have an impact on liver damage in CHB. Neither PNPLA3 nor TM6SF2 genotype was associated with hepatic inflammation or fibrosis (Tables 1  and 2 CC, homozygotes for the C allele; CT, heterozygotes; TT, homozygotes for the T allele. The association between the rs641738 variant and the histological features has been tested by multivariate ordinal regression analysis adjusted for age, sex, BMI, T2DM, recruitment center, PNPLA3 and TM6SF2 genotypes, viral load, and HBeAg status. P values represent the significance of a trend in prevalence of more-severe degree of histological features among genotypes. Genetic analyses were estimated by adopting an additive model, except for TM6SF2, where a dominant model was used owing to few homozygotes for the minor allele.
TM6SF2, and MBOAT7 variants on liver injury traits were observed.
MBOAT7 AND HEPATIC STEATOSIS
Next, we undertook secondary analysis for the association of rs641738 with steatosis; scoring was available in 957 (87%) subjects. The characteristics of the subcohort with steatosis scoring were similar to the overall cohort. As a positive control, and consistent with earlier reports, (17) PNPLA3 rs738409 and TM6SF2 rs58542926 minor alleles were significantly associated with the presence of any steatosis (Supporting Table  S5 ) and severe steatosis (S2; Supporting Table S6) in the total population and when stratified by ethnicity. In contrast, rs641738 (T) had no impact on the presence of steatosis, including when stratified by ethnicity or adopting different genetic models (i.e., dominant model for the minor allele; Fig. 1 ; Supporting Tables  S5 and S6 ).
rs641738 GENOTYPE ASSOCIATES WITH MBOAT7 mRNA EXPRESSION IN LIVER
Finally, we investigated the functional basis for the association between liver damage and rs641738 in CHB by testing the effect of this SNP on hepatic gene expression in a well-characterized subcohort of 42 patients; their characteristics are summarized in Supporting Table S7 and matched the overall cohort. Under both the additive and dominant models, rs641738 genotype was associated with MBOAT7 expression (Fig. 3A) , consistent with studies in HCV and NAFLD. (4, 6) Interestingly, the SNP maps to DNasehypersensitive sites in multiple cell lines and alters the binding motifs of transcription factors. These include some that have been reported to modulate inflammation and fibrosis, such as small mothers of decapentaplegic 4 (SMAD4), a key regulator of the diverse roles of transforming growth factor (TGF)-b1 in inflammation and fibrosis (Fig. 3B) . (29) Furthermore, the X protein of HBV can activate the TGF-b pathway through direct interaction with SMAD4. (30) We examined for clinical parameters associated with hepatic MBOAT7 based on their expression above or below the mean MBOAT7 mRNA level. MBOAT7 expression correlated with hepatic inflammation (P 5 0.01), serum ALT (P 5 0.02), and gamma-glutamyl transpeptidase (P 5 0.048), but not to other characteristics (age, sex, ethnicity, T2DM, BMI, blood glucose, lipid profile, viral load and HBeAg status, and PNPLA3 or TM6SF2 genotypes). This remained significant for inflammation in multivariate analysis (OR 5 0.23; 95 CI%, 0.06-0.80; P 5 0.02; Fig. 3 ; Supporting Table S8) .
Last, to examine whether the differential relative risk between white and Chinese patients was attributed to differences in linkage disequilibrium (LD) between rs641738 and any other potential functional SNPs, we located the set of SNPs that are in strong LD (r 2 0.8) with rs641738 in all four HapMap 2 populations, and annotated the potential function of each SNP in this set using HaploReg. (23) In all populations, rs641738 was not linked with any nonsynonymous functional variants or potential functional SNPs apart from rs8736 in the 3 0 UTR (untranslated region) of Genetic analyses were undertaken using an additive model for PNPLA3 and MBOAT7 and a dominant model for TM6SF2 (because of only a few homozygotes for the 167K mutant allele).
MBOAT7; this was in perfect LD with rs641738 in all populations (Supporting Table S9 ).
Discussion
In this study exploring the role of polymorphisms at MBOAT7 rs641738 in patients with CHB, we demonstrate that carriage of the minor allele is associated with hepatic inflammation and fibrosis, but not steatosis. This effect was independent of other risk factors, including age at time of biopsy, sex, HBeAg status, viral load, ALT, ethnicity, BMI, T2DM, recruitment center, and variation at PNPLA3 rs738409 and TM6SF2 rs58542926. Functionally, carriers of the minor allele had reduced liver gene expression, and the latter was associated with severity of hepatic inflammation and liver enzymes. Finally, neither PNPLA3 rs738409 nor TM6SF2 rs58542926 were associated with inflammation and fibrosis, though they were associated with steatosis. Collectively, in the context of other published reports, (4) (5) (6) these results indicate that MBOAT7 is a risk locus for inflammation (and consequently fibrosis) across multiple liver diseases.
From a functional perspective, the rs641738 minor risk allele is consistently associated with reduced hepatic mRNA and protein, (4, 6) suggesting reduced enzymatic activity, as also confirmed by lower arachidonoyl-phosphatidylinositol/total phosphatidylinositol ratios. (4, 5) Furthermore, it maps to DNasehypersensitive sites, including those relevant to liver diseases, and alters the binding motifs of transcription factors that modulate inflammation and fibrosis such as SMAD4. Hence, whereas the detailed functional mechanisms of MBOAT7 action are not completely known, expression is inversely associated with severity of hepatic inflammation and ALT levels, both indicative of liver injury. Some hypotheses can be postulated. For example, we have shown robust MBOAT7 expression in most common immune cell subsets (6) ; it also modulates eicosanoid production by neutrophils (7) and myeloid cells (31) and correlates with the induction of T-cell proliferation. (32) This suggests that MBOAT7 activity could regulate inflammatory activity. Additionally, in the liver, free AA and eicosanoids induce apoptosis, (33) a potent trigger for inflammation and hence amplify the immune response. (7, 10) In this regard, up-regulation of MBOAT7 in response to an insult (e.g., viral hepatitis infection) might be a compensatory or adaptive mechanism to overcome pathogen-induced liver damage, similar to that observed in contexts such as intrauterine growth restriction and shock. (34) Further studies are required to understand the mechanisms of MBOAT7 function and to explore the role of MBOAT7 in the regulation of inflammatory cell activity.
The MBOAT7 rs641738 SNP, in relation to a disease phenotype, was first identified as a marker of cirrhosis in alcoholic liver disease (ALD). (3) Subsequently, carriage of the minor allele was reported to be associated with hepatic steatosis and more-severe fatty liver disease. (4, 5) In our secondary analysis, MBOAT7 rs641738 had no effect on steatosis in CHB, as we have also shown in CHC. (6) Prevalence of steatosis was 45%, similar to that previously reported in CHB (13, 35) ; the large cohort size makes this less likely as a reason for the lack of association. However, the possibility that rs641738 could have a weak effect would need a larger cohort size to definitively refute or confirm an effect. Furthermore, as positive control, both PNPLA3 and TM6SF2 had an association with steatosis in CHB, implying that the impact of rs641738 on steatosis is likely marginal. Notably, recent reports consistently demonstrate that liverspecific gene deletion of the related Mboat5 (Lpcat3) exacerbates hepatic inflammation and macrophage infiltration, whereas it has no significant effect on lipid accumulation when mice are fed normal chow. (36, 37) In toto, this suggests that inflammation is the driver for MBOAT7-mediated fibrosis, a hypothesis consistent with all published data. (3) (4) (5) (6) Interestingly, similar to earlier reports, (13, 17) we show that neither PNPLA3 nor TM6SF2, both implicated in hepatic lipid trapping, had any significant influence on liver damage in CHB. This contrasts with their influence on disease severity in NAFLD, ALD, and CHC. (17, 27, 28) Of relevance, multiple reports (13, 35) and a meta-analysis (38) failed to ascertain any association between steatosis and inflammation or fibrosis in CHB. Thus, the extent of hepatic triglyceride accumulation is less likely a driver of damage in hepatitis B, with immune-mediated mechanisms more prominent.
We observed ethnic differences in allele frequency of the MBOAT7 rs641738 polymorphism between whites (MAF 5 0.45) and East Asians (0.24), as also in the healthy population from the 1000 Genome and HapMap 2 cohorts. rs641738 had a differential genotypic relative risk, given that the effect was stronger in whites. Multiple hypotheses for this can be entertained. First, the contribution of an allele in any given population depends upon its allele frequency, (39) and, second, population-specific genotypic effects have been reported. (40) The latter might be attributed to differing linkage disequilibrium patterns with causal variants. In investigating for this, for all four HapMap 2 populations (European, Chinese, Japanese, and African), rs641738 was not linked with any nonsynonymous functional variants or potential functional SNPs apart from rs8736 in the 3 0 UTR of MBOAT7, to which it is in perfect LD. The fact that the rs641738 effect is strengthened by the combination of two ethnic groups might suggest that this is the causal variant or that it might be attributed to the increase in sample size. Another possibility is that the ethnic difference is attributed to greater alcohol intake among whites compared to Chinese. However, in our cohort, we did not observe a difference in alcohol intake between whites and Chinese, and this could be attributed to the reported increase in the prevalence of alcohol intake among Asians. (41) It is noteworthy that in concordance with previous data in CHC and NAFLD, we did not observe any association between rs641738 and alcohol intake. (4, 6) To our knowledge, no studies have explored the role of MBOAT7 to liver injury in Chinese populations for any liver disease, and thus further studies are required.
Our study has some limitations, including missing data on the use of alcohol. The rates of alcohol consumption were similar to the prevalence in CHB patients reported elsewhere. (13) Furthermore, data on alcohol consumption is expected to be missing at random, and indeed the availability of alcohol consumption data was not associated with liver injury. Finally, when imputing missing values, the OR of rs641738 for liver damage remained essentially unaltered.
Previous data in CHC and NAFLD also indicate that rs641738 did not associate with mean alcohol intake or severe alcohol intake. (4, 6) Another limitation is missing data on HBV genotype. Finally, the sample size of the PCR subcohort is relatively small; however, our transcript data are consistent with similar data in CHC and NAFLD, (4, 6) as well as publically available eQTL data. (42) In conclusion, we provide strong evidence that MBOAT7 rs641738 contributes to hepatic inflammation and fibrosis in patients with CHB. In concert with previous data in ALD, NAFLD and HCV, the functional role of this variant across all liver phenotypes is likely through the modulation of inflammation. Further studies are needed to independently confirm these findings and to explore the detailed functional mechanisms of MBOAT7 effects on inflammation and its potential as a therapeutic target to reduce inflammation.
